Nivolumab plus AVD “should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” according to researchers.
The FDA grants rare pediatric disease designation for serious or life-threatening diseases that affect fewer than 200,000 people in the United States when those people are primarily younger than 18 ...
The ATS provided guidance on how health care systems facing shortages can conserve IV fluids and address the shortages. Tips include: Reconfigure electronic health records to guide appropriate ...
Patients with EGFR-mutant, oligometastatic NSCLC who received radiotherapy plus icotinib had longer overall and progression-free survival than those who received icotinib alone.